Target and Its Patented Drug(s)

Content Navigation (  All   None )                                      
Target General Information
Patent(s) and the Corresponding Patented Drug(s)
References
Target General Information  Top
Target ID T77613 Target Info
Target Name Phosphodiesterase 1B (PDE1B)
Synonyms PDES1B; PDE1B1; CamPDE 1B; Cam-PDE 1B; Calcium/calmodulindependent 3',5'cyclicnucleotide phosphodiesterase 1B; Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; 63 kDa CamPDE; 63 kDa Cam-PDE
Target Type Patented-recorded Target
Gene Name PDE1B
Biochemical Class Phosphoric diester hydrolase
UniProt ID
PDE1B_HUMAN
Patent(s) and the Corresponding Patented Drug(s)  Top
United States Patent and Trademark Office (USPTO)
Patent ID US9598426
Title Organic compounds
Abstract Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Applicant(s) INTRA-CELLULAR THERAPIES, INC.
Representative Drug(s) D0E9JC Drug Info N.A. Click to Show More [1]
2 D0Z1CK Drug Info N.A. [1]
3 D0HO1Q Drug Info N.A. [1]
Patent ID US9598426
Title Organic compounds
Abstract Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Applicant(s) INTRA-CELLULAR THERAPIES, INC.
Representative Drug(s) D0E9JC Drug Info N.A. Click to Show More [1]
2 D0Z1CK Drug Info N.A. [1]
3 D0HO1Q Drug Info N.A. [1]
Patent ID US9598426
Title Organic compounds
Abstract Provided are PDE1 inhibitors of Formula I, processes for their production and their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Applicant(s) INTRA-CELLULAR THERAPIES, INC.
Representative Drug(s) D0E9JC Drug Info N.A. Click to Show More [1]
2 D0Z1CK Drug Info N.A. [1]
3 D0HO1Q Drug Info N.A. [1]
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Patent ID US9173884
Title Inhibitors of phosphodiesterase 11 (PDE11)
Abstract The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject.
Applicant(s) Trustees of Boston College
Patent ID US10105367
Title Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones
Abstract Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
Applicant(s) DART NEUROSCIENCE (CAYMAN) LTD.
Representative Drug(s) D0WS3T Drug Info IC50 < 100nM [3]
Patent ID US10092575
Title Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
Abstract Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
Applicant(s) Dart NeuroScience (Cayman) Ltd.
Representative Drug(s) D0NI7A Drug Info N.A. Click to Show More [4]
2 D03GTM Drug Info N.A. [4]
3 D0J1LK Drug Info N.A. [4]
Patent ID US10092575
Title Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
Abstract Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
Applicant(s) Dart NeuroScience (Cayman) Ltd.
Representative Drug(s) D0NI7A Drug Info N.A. Click to Show More [4]
2 D03GTM Drug Info N.A. [4]
3 D0J1LK Drug Info N.A. [4]
Patent ID US10092575
Title Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
Abstract Described herein are compounds and chemical entities of Formula I, methods of their synthesis, compositions comprising them, and their use in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders.
Applicant(s) Dart NeuroScience (Cayman) Ltd.
Representative Drug(s) D0NI7A Drug Info N.A. Click to Show More [4]
2 D03GTM Drug Info N.A. [4]
3 D0J1LK Drug Info N.A. [4]
Patent ID US10034861
Title 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
Abstract The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Applicant(s) H. Lundbeck A/S
Representative Drug(s) D06WJK Drug Info IC50 = 1.6 nM Click to Show More [5]
2 D0V8ZY Drug Info IC50 = 1.6 nM [5]
3 D00LVD Drug Info IC50 = 5.9 nM [5]
Patent ID US10034861
Title 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
Abstract The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Applicant(s) H. Lundbeck A/S
Representative Drug(s) D06WJK Drug Info IC50 = 1.6 nM Click to Show More [5]
2 D0V8ZY Drug Info IC50 = 1.6 nM [5]
3 D00LVD Drug Info IC50 = 5.9 nM [5]
Patent ID US10034861
Title 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
Abstract The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Applicant(s) H. Lundbeck A/S
Representative Drug(s) D06WJK Drug Info IC50 = 1.6 nM Click to Show More [5]
2 D0V8ZY Drug Info IC50 = 1.6 nM [5]
3 D00LVD Drug Info IC50 = 5.9 nM [5]
References  Top
REF 1 Organic compounds. US9598426.
REF 2 Inhibitors of phosphodiesterase 11 (PDE11). US9173884.
REF 3 Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367.
REF 4 Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575.
REF 5 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.